Importantly, our findings suggest that TP/HCPT trigger apoptosis in human lung cancer cells by activation of p38 and ERK MAPK cascades, and inhibition of the Akt survival pathway through a mechanism involving activation of PP2A, which uncover a molecular mechanism that may underlie this combinatorial therapy (Fig. 7). The gene discussed is PTPA; the disease is lung carcinoma.